# MDWD catalysts: MediWound Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mdwd/catalysts

> MediWound Ltd. (MDWD) has 6 upcoming catalysts. The next is the escharex (ex-03) primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | MediWound Ltd. |
| Ticker | MDWD (Nasdaq) |
| SEC CIK | 1593984 |
| SIC | 2833 |
| SEC filings | https://sec-api.dev/companies/mdwd |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 25, 2021 | [NexoBrid (anacaulase) complete response letter (CRL)](https://sec-api.dev/pdufa/anacaulase) | MDWD |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761192_2023_Orig1s000OtherActionLtrs.pdf%22)) |
| December 28, 2022 | [NexoBrid (anacaulase) FDA approval](https://sec-api.dev/pdufa/anacaulase) | MDWD | To remove eschar in adults with deep partial thickness or full thickness thermal burns | completed, approved | "NexoBrid \| anacaulase-bcdb \| 12/28/2022 \| To remove eschar in adults with deep partial thickness or full thickness thermal burnsDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| August 15, 2024 | [NexoBrid (anacaulase) label expansion decision](https://sec-api.dev/pdufa/anacaulase) | MDWD |  | completed, approved | "BLA761192 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20240815, review_priority STANDARD; sponsor_name MEDIWOUND, LTD; product NEXOBRID (ANACAULASE-BCDB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761192%22)) |
| December 2026 | [Escharex (ex-03) primary completion](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568627)) |
| Dec 2026 to Mar 2027 | [Escharex (ex-03) topline data readout](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568627)) |
| August 2028 | [Gel vehicle primary completion](https://sec-api.dev/pdufa/gel-vehicle) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT07692178 (An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07692178)) |
| Aug to Nov 2028 | [Gel vehicle topline data readout](https://sec-api.dev/pdufa/gel-vehicle) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT07692178 (An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07692178)) |
| Nov 2028 to Feb 2029 | [Escharex (ex-03) topline data readout](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venus Leg Ulcers | scheduled | "NCT06690177 (Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11-04 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06690177)) |
| November 2028 | [Escharex (ex-03) primary completion](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venus Leg Ulcers | scheduled | "NCT06690177 (Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11-04 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06690177)) |

## Drugs

- [NexoBrid (anacaulase)](https://sec-api.dev/pdufa/anacaulase): deep partial-thickness and/or full-thickness thermal burns, To remove eschar in adults with deep partial thickness or full thickness thermal burns
- [Escharex (ex-03)](https://sec-api.dev/pdufa/escharex-ex-03): Venous Leg Ulcer (VLU), Venus Leg Ulcers
- [Gel vehicle](https://sec-api.dev/pdufa/gel-vehicle): Venous Leg Ulcer (VLU)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mdwd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MDWD catalysts: MediWound Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mdwd/catalysts

```bibtex
@misc{secapidev_companies_mdwd_catalysts_20261116,
  title        = {MDWD catalysts: MediWound Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mdwd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mdwd_catalysts_20261116","title":"MDWD catalysts: MediWound Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mdwd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
